The choices made by the research and development team are central to the commercialization of every pharma product, for example, about evidence generation during clinical trials.
Despite this, the commercial team’s involvement in pharmaceutical launches traditionally only begins in earnest during late Phase II or Phase III, after the release of the evidence and much of the value of the drug has been fixed.
Only then does the team seek to capitalize on the already defined profile of a product. However, to successfully launch a drug in the complex and hypercompetitive environment of today, pharma needs to think differently.
Success is dependent on considering where the product fits into the market today and tomorrow. This means pre-empting the competition, carving out a differentiated story and building the capability to deliver it. For the best results, start that process in the early stages of product development, while the evidence generation strategy is underway.
Blue Latitude Health , a member of Fishawack Health speaks to Mark Assenti, Managing Consultant and the Head of our Early Stage Strategy service, about how this new way of thinking breeds successful product launches.
What is Early stage strategy?
MA: The pharma market is more competitive than ever before, and the way we interact with customers – including the patient – is changing. On top of this, there are new practices in the way healthcare is organized. The market is evolving, so it’s now more important than ever to assess the portfolio early on to optimize value.
To read the full article, fill out the form below to receive the PDF.